[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631059":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":63,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":89,"whyStopped":26,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Foundation University Islamabad","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Topical 3% tranexamic acid solution","ACTIVE_COMPARATOR","nightly tranexamic acid for 12 weeks with mineral sunscreen",[13],"Drug: topical 3% tranexamic acid solution",{"label":15,"type":16,"description":17,"interventionNames":18},"topical 30% metfomin cream","EXPERIMENTAL","Participants will apply topical 30% metformin cream, once nightly on the affected facial area for 12 weeks, with use of mineral sunscreen",[19],"Drug: Topical 30% metformin cream",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","topical 3% tranexamic acid solution","nightly topical 3% tranexamic acid solution for 12 weeks with mineral sunscreen",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Topical 30% metformin cream","Participants will apply topical 30% metformin once a night for 12 weeks, with concurrent use of mineral sunscreen.",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Dr. Bad e Harum, FCPS, Fellowship in Derma","CONTACT","+923335090999","harum_bade@yahoo.com",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Dr. Arfan ul Bari, FCPS Derma","+923016547007","albariul@gmail.com",[42],{"facility":43,"status":26,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Fauji Foundation Hospital, Rawalpindi","Rawalpindi","Punjab Province","44000","Pakistan","PK",{"type":50,"coordinates":51},"Point",[52,53],73.0479,33.59733,{"lat":53,"lon":52},[56,60],{"name":57,"role":34,"phone":58,"phoneExt":26,"email":59},"Ayesha Saeed, PhD","+923325756579","ayeshasaeed@fui.edu.pk",{"name":61,"role":62,"phone":26,"phoneExt":26,"email":26},"Dr. Bad e Harum, FCPS","PRINCIPAL_INVESTIGATOR",{"type":64,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100631059","comparative-evaluation-of-topical-metformin-and-topical-tranexamic-acid-in-melasma-100631059",false,"NCT07495748","Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma","Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma Using MASI Score Reduction: A Randomized Controlled Trial","Melasma","Inclusion Criteria:\n\n* Patients aged 18-50 years\n\n  * Clinically diagnosed facial melasma\n  * Both genders\n  * Patients willing to give informed consent\n\nExclusion Criteria:\n\n* • Pregnant or lactating women\n\n  * Patients using systemic or topical melasma treatments in the previous 4 weeks\n  * Known hypersensitivity to study medications\n  * Presence of other facial dermatoses\n  * History of photosensitivity disorders","ALL","18 Years","50 Years",{"count":77,"type":78},70,"ESTIMATED","INTERVENTIONAL",[81],"NA","This randomised controlled trial aims to compare the efficacy of topical metformin (30%) and topical tranexamic acid (3%) in the treatment of melasma using reduction in the Melasma Area and Severity Index (MASI) score over 12 weeks. Melasma is a common hyperpigmentation disorder with significant cosmetic and psychological impact, and current treatments often have limitations. Both metformin and tranexamic acid have shown promising depigmenting effects through different mechanisms. A total of 70 patients will be enrolled and randomly divided into two groups. Participants will apply the assigned treatment once daily along with sunscreen and will be assessed at baseline and at 4, 8, and 12 weeks. The primary outcome is MASI score reduction, while secondary outcomes include patient-reported improvement and safety. This study seeks to provide comparative evidence for safer and more effective treatment options for melasma management.",[71],[71,85,86,87,88],"topical metformin","topical tranexamic acid","hyper-pigmentation","MASI","NOT_YET_RECRUITING","2026-03-24",{"date":92,"type":93},"2026-03-27","ACTUAL",{"date":95,"type":78},"2026-07-01",{"date":97,"type":78},"2027-07-01",{"name":5,"class":6},1]